NYSE:GSK 11 November 2025 - 20 December 2025

GSK plc stock is in focus on Dec. 17 after a major U.S. regulatory win: the FDA approved Exdensur for severe asthma—giving GSK a new, ultra‑long‑acting biologic that’s dosed just twice a year. The approval lands as the company approaches a leadership handover on Jan. 1, 2026, and as investors weigh whether GSK’s late‑2025 pipeline momentum can translate into durable earnings growth in 2026 and beyond. Reuters+2GSK+2

GSK plc stock is ending 2025 with a rare “cluster” of market-moving catalysts packed into the same two-week window: fresh U.S. regulatory momentum for a new antibiotic, European regulatory backing for multiple respiratory products, and an imminent FDA decision that could reshape GSK’s long-term outlook in severe asthma and nasal polyps.

GSK plc is ending the week in the spotlight after a cluster of regulatory updates in Europe and the United States—exactly the kind of “catalyst stacking” that can shift the narrative around a big pharma stock from defensive dividend name to pipeline and launch execution story. Add in an active share buyback program, a clearly mapped dividend calendar, and an incoming CEO transition in early 2026, and GSK stock has plenty for investors to digest heading into year-end. GSK+3Reuters+3Reuters+3

London, 20 November 2025 — GSK plc finished Thursday’s session slightly higher, as upbeat broker commentary and a string of recent R&D announcements helped support the pharma giant’s share price against a volatile FTSE 100 backdrop.

As London investors get ready for the opening bell on Monday, 17 November 2025, GSK plc is entering the week in a strong but finely balanced position: the shares sit close to their 52‑week highs, the company has just gone ex‑dividend, buybacks are running hard, guidance has been upgraded, key drugs have hit major regulatory milestones – and legacy Zantac litigation is easing but not gone.